Replies to post #156685 on Biotech Values

[DewDiligence]

GILD/ABBV/BMY/etc—The bind now is very few classes of HCV drugs work in GT3 outside of nukes. The greatest progress looks to be in the NS5A class with work to be done. GILD mentioned they are working on a second pre-clinical nuke…

Have you completely discounted the possibility that extending treatment from 12w to 16w will make a material difference in the FUSION study? (You did not reply to #msg-84224590.) I think it’s unlikely, but not hopeless.